NEW ORLEANS, LA – The U.S. Food and Drug Administration (FDA) has approved FARXIGA™ (dapagliflozin) to treat type 2 diabetes, marking a major advancement in SGLT2 inhibitor therapy developed by AstraZeneca and Bristol-Myers Squibb. FARXIGA is a once-daily oral SGLT2 inhibitor developed as an adjunct to diet and exercise for improving glycaemic control in adults with type 2 diabetes. This approval represents a significant advancement for adults struggling to manage blood sugar levels and introduces a new option for healthcare providers aiming to tailor individualized treatment plans. Tyler Hastings, Managing Partner at DelRicht Research, emphasizes the trial’s clinical outcomes and DelRicht’s contribution to its success.

Dr. Patrick Dennis, Principal Investigator at Touro Medical Center in New Orleans, LA, led a key clinical site contributing to this approval in partnership with DelRicht Research. Dr. Dennis has conducted multiple clinical trials with DelRicht across multiple therapeutic areas, consistently demonstrating leadership in high-quality clinical research execution.

Tyler Hastings on How FARXIGA Addresses the Burden of Type 2 Diabetes

The FARXIGA clinical program included more than 11,000 adults across 24 clinical trials, including patients with diverse backgrounds and varying comorbidities. The approval was based on data showing FARXIGA’s ability to significantly reduce HbA1c levels, body weight, and systolic blood pressure compared to placebo when added to existing therapy. Importantly, the treatment class, SGLT2 inhibitors, represents a novel mechanism by enabling glucose excretion through the urine rather than insulin modulation.

“Type 2 diabetes continues to affect millions globally, and FARXIGA offers a meaningful new option for patients and providers alike,” said Tyler Hastings, Managing Partner at DelRicht Research. “We are proud to have contributed to the development of this therapy and to continue working with investigators like Dr. Dennis, who are committed to advancing care for people living with chronic disease.”

“We are proud to have contributed to the development of this therapy and to continue working with investigators like Dr. Dennis, who are committed to advancing care for people living with chronic disease.”

— Tyler Hastings, Managing Partner at DelRicht Research

DelRicht’s Local Site Contribution to FARXIGA’s Global Approval

The FDA approval of FARXIGA highlights not only a milestone in diabetes management but also the critical role clinical sites play in advancing treatments. The involvement of Dr. Dennis and the Touro Medical Center site demonstrates the power of experienced local research in supporting global therapeutic innovation. DelRicht’s ability to engage patients across diverse demographics further ensures that outcomes reflect real-world populations and needs.

FARXIGA is part of a broader movement toward patient-tailored diabetes therapies that reduce long-term cardiovascular risks and improve quality of life. It also demonstrates the value of targeting the kidneys, a key organ in glucose regulation, rather than the pancreas alone.

“As a physician, contributing to the FARXIGA trial gave me the opportunity to support new pathways for patients with diabetes,” said Dr. Patrick Dennis. “This approval provides a critical addition to the treatment toolbox and represents progress for patients who need alternatives.”

“As a physician, contributing to the FARXIGA trial gave me the opportunity to support new pathways for patients with diabetes. This approval provides a critical addition to the treatment toolbox and represents progress for patients who need alternatives.”

— Dr. Patrick Dennis, Principal Investigator at DelRicht Research

DelRicht Research and Dr. Dennis: Advancing Type 2 Diabetes Therapies

With its approval in over 40 countries and expanding data from the DECLARE cardiovascular outcomes trial, this SGLT2 inhibitor’s FDA approval represents a major step forward in individualized treatment for type 2 diabetes.

DelRicht Research remains committed to supporting breakthrough treatments through strong site partnerships and experienced investigators, with a deep focus on improving patient outcomes.

Learn more in the full press release from AstraZeneca.